1478OResults of the ASCEND-7 phase II study evaluating ALK inhibitor (ALKi) ceritinib in patients (pts) with ALK+ non-small cell lung cancer (NSCLC) metastatic to the brain

ConclusionsEfficacy of ceritinib, either in pts with or without a prior exposure to crizotinib, as reported in other studies, is confirmed in this study where only pts with active brain metastases were eligible. Safety profile of ceritinib in these pts remain consistent to what was reported earlier.Clinical trial identificationNCT02336451.Editorial acknowledgementShiva Krishna Rachamadugu, Novartis Healthcare Pvt Ltd, Hyderabad, India.Legal entity responsible for the studyNovartis Pharmaceuticals Corporation.FundingNovartis Pharmaceuticals Corporation.DisclosureL.Q. Chow: Advisory / Consultancy, Consultation Honoraria/Review panel: Amgen; Advisory / Consultancy, Research grant / Funding (institution): Novartis; Advisory / Consultancy, Research grant / Funding (institution): Merck; Research grant / Funding (institution): Lilly/Imclone; Advisory / Consultancy, Research grant / Funding (institution): Bristol-Myers Squibb; Advisory / Consultancy, Research grant / Funding (institution): AstraZeneca/MedImmune ; Advisory / Consultancy, Research grant / Funding (institution): Pfizer; Research grant / Funding (institution): Incyte; Advisory / Consultancy: Takeda; Research grant / Funding (institution): VentiRx; Advisory / Consultancy: Sanofi-Genzyme; Advisory / Consultancy, Research grant / Funding (institution): Seattle Genetics; Advisory / Consultancy, Research grant / Funding (institution): Dynavax; Advisory / Consultancy, Research grant / Funding (institution): Genentech; Advisory...
Source: Annals of Oncology - Category: Cancer & Oncology Source Type: research